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Abstract
Background
Dolutegravir (DTG) is a once-daily unboosted second-generation integrase-inhibitor that
along with two nucleoside reverse transcriptase inhibitors is one of several regimens rec-
ommended by the United States, United Kingdom and European Union for first-line antire-
troviral treatment of people with HIV infection. Our objective was to review the evidence for
the efficacy and safety of DTG-based first-line regimens compared to efavirenz (EFV)-
based regimens.
Methods
We conducted a systematic review. We comprehensively searched a range of databases
as well as conference abstracts and a trials registry. We used Cochrane methods in screen-
ing and data collection and assessed each study’s risk of bias with the Cochrane tool. We
meta-analyzed data using a fixed-effects model. We used GRADE to assess evidence
quality.
Results
From 492 search results, we identified two randomized controlled trials, reported in five
peer-reviewed articles and one conference abstract. One trial tested two DTG-based regi-
mens (DTG + abacavir (ABC) + lamivudine (3TC) or DTG + tenofovir + emtricitabine)
against an EFV-based regimen (EFV+ ABC+3TC). The other trial tested DTG+ABC+3TC
against EFV+ABC+3TC. In meta-analysis, DTG-containing regimens were superior to
EFV-containing regimens at 48 weeks and at 96 weeks (RR = 1.10, 95% CI 1.04–1.16; and
RR = 1.12, 95% CI 1.04–1.21, respectively). In one trial, the DTG-containing regimen was
superior at 144 weeks (RR = 1.13, 95% CI 1.02–1.24). DTG-containing regimens were
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superior in reducing treatment discontinuation compared to those containing EFV at 96
weeks and at 144 weeks (RR = 0.27, 95% CI 0.15–0.50; and RR = 0.28, 95% CI 0.16–0.48,
respectively). Risk of serious adverse events was similar in each regimen at 96 weeks
(RR = 1.15, 95% CI 0.80–1.63) and 144 weeks (RR = 0.93, 95% CI 0.68–1.29). Risk of bias
was moderate overall, as was GRADE evidence quality.
Conclusions
DTG-based regimens should be considered in future World Health Organization guidelines
for initial HIV treatment.
Introduction
Dolutegravir (DTG) is a once-daily unboosted second-generation integrase-inhibitor [1,2] that
along with two nucleoside reverse transcriptase inhibitors (NRTI) is the third agent in two of the
United States (U.S.) Department of Health and Human Services’ and the European AIDS Clinical
Society’s six recommended initial regimens for antiretroviral-naïve HIV-infected patients [3,4].
The British HIVMedical Association has also recommended it as one of six third agents to be
usedwith a two-drugNRTI backbone [5]. DTG has a very low resistance profile and a low risk of
drug-drug interactions and is available in a fixed dose combination (with abacavir [ABC] and
lamivudine [3TC]). Unlike elvitegravir (EVG) [6,7], another integrase inhibitor, DTG does not
require boosting.DTG’s efficacyhas been evaluated in five Phase IIb, III and IIIb trials, which
have involved 1,579 patients [8]. In four studies, participants were ART-naïve (SPRING-1 [9],
SPRING-2 [10], SINGLE [11] and FLAMINGO [12]); in one study, participants were ART-expe-
rienced but integrase inhibitor-naïve (SAILING) [13].
In contrast to U.S., European and British recommendations, currentWorld Health Organi-
zation (WHO) guidelines call for initial therapy with two NRTIs, tenofovir disoproxil fumarate
(TDF) and either 3TC or emtricitabine (FTC), plus the non-nucleoside reverse transcriptase
inhibitor (NNRTI) efavirenz (EFV) as the preferred regimen in non-pregnant and non-breast-
feeding adults [14]. However, EFV in particular has a less than ideal toxicity profile, which pri-
marily includes neuropsychiatric symptoms in up to 50% of patients ranging from dizziness,
insomnia and abnormal dreams to depression and suicide [15,16]. For this reason, it has been
replaced with integrase inhibitors and the boosted protease inhibitor darunavir/ritonavir for
first-line therapy in many high-income countries [3–5]; these regimens have the added benefit
of reducing viral load more rapidly. Based on head-to-head comparisons with the original
licensed integrase inhibitor, raltegravir, DTG appears to be non-inferior in one trial with ART-
naïve patients [10] and superior in terms of efficacy and non-discontinuation in another [12].
WHO lists initial therapy with TDF + 3TC + DTG or TDF + FTC + DTG as an alternative
first-line regimen, while noting that safety and efficacy data on its use in pregnant women, peo-
ple coinfectedwith HIV and TB and children<12 years old are unavailable [14].
We anticipate that in the next round of WHO recommendations, serious consideration will
be given to broadening recommendations for first-line ART to include DTG and possibly daru-
navir/ritonavir. Part of theWHO process requires carefully conducted systematic reviews to
determine the extent and strength of the evidence that can support such a recommendation. In
this paper we systematically review the efficacy and safety of DTG in combination with two
NRTIs compared to the currentWHO standard regimen of EFV with two NRTIs. The two
NRTI backbones that we examine include ABC/3TC/DTGand TDF/3TC or FTC plus DTG.
DTG vs. EFV for Initial ART
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Methods
We used CochraneCollaborationmethods [17] throughout the review process and follow the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance
[18] in reporting our review. We registered our review protocol in the PROSPERO online regis-
try (registration number CRD42014013233).
Search methods
We formulated a comprehensive and exhaustive search strategy in an effort to identify all rele-
vant studies. We searched the CochraneCentral Register of Controlled Trials, Embase, Litera-
tura Latino Americana em Ciências da Saúde (LILACS), PubMed andWeb of Science. Our
search strategy includedMedical Subject Heading (MeSH) terms and a range of relevant key-
words and covered all records up to the search date (16 March 2016). See S1 Table for our
PubMed search strategy, which we modified and adapted as needed for use in the other
databases.
We also searched all available abstracts from the Conference on Retroviruses and Opportu-
nistic Infections, the International AIDS Conference, and the International AIDS Society Con-
ference on HIV Pathogenesis, Treatment and Prevention throughMarch 2016. We searched
for ongoing trials in the clinical trials registry (clinicaltrials.gov) at the U.S. National Institutes
of Health. Our searches were iterative, in that we searched bibliographies of included and other
highly relevant studies for additional references. Studies published in any language were eligible
for inclusion. Publication status was not an eligibility criterion.
Inclusion and exclusion criteria
We included RCTs that compared clinical and laboratory outcomes in HIV-1-infected, ART-
naïve adult patients starting regimens of DTG plus two NRTIs with those who started on regi-
mens of EFV plus two NRTIs. We excluded non-randomized studies, studies in which partici-
pants were ART-experienced and studies in which DTG was compared to boosted PI
regimens.
Data extraction
We imported search results into bibliographic citation management software (EndNote X7,
Thomson Reuters, New York, New York, USA) and excluded duplicate references. Reviewing
only article titles, one author (HH) excluded all references that were clearly irrelevant. Two
authors (GWR and HH), working independently, then reviewed the titles, abstracts and
descriptor terms of the remaining citations to identify potentially eligible reports.We obtained
full text articles for all references identified as potentially meeting inclusion criteria. GWR and
HH reviewed these full text articles and applied inclusion criteria to establish each study's eligi-
bility or ineligibility. Our plan was to resolve any differences of opinion through discussion
and, if necessary, a neutral third party arbiter.
After identifying trials for inclusion, two authors (GWR and HH) independently examined
and extracted data from each study. GWR and HH separately entered these data into standard-
ized data extraction forms and then compared extracted data. There were no disagreements.
Risk of bias assessment
We used the CochraneCollaboration tool for assessing risk of bias in the included RCTs [17].
The Cochrane tool assesses risk of bias in individual studies in six domains: sequence
DTG vs. EFV for Initial ART
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generation, allocation concealment, blinding, incomplete outcome data, selective outcome
reporting and other potential biases.
Data synthesis and analysis
We assessed efficacyusing the relative risk (RR) for dichotomous outcomes and mean differ-
ence (MD) for continuous outcomes, each with its 95% confidence interval (CI).Where appro-
priate and possible, we pooled data across studies and estimated summary effect sizes, using a
Mantel-Haenszel fixed-effectsmeta-analytic model.We performed all meta-analyses in Review
Manager 5.3 (CochraneCollaboration, London, UK). Our outcome measures, which were pre-
specified in the protocol, included clinical progression, death, viral suppression to non-detect-
able levels, discontinuation of therapy, immunologic recovery, acquired resistance and Grade
III and IV severe adverse reactions.We did not pre-specify specific adverse events.
We present estimates of heterogeneity, determined by the I2 statistic. Estimates of I2 are
interpreted as the percentage of variability in effect estimates due to heterogeneity rather than
to chance. We would have conducted sensitivity analyses had it been necessary to investigate
heterogeneity in pooled data. We also pre-specified a sub-group analysis to compare NRTI
backbones (TDF+FTC or 3TC vs. ABC+3TC)with DTG-based therapy.
We used the GRADE approach to assess the quality of evidence for each outcome across the
literature [19]. In GRADE, “quality of evidence” is defined as “the extent of our confidence that
the estimates of effect are correct" [17]. The quality rating across studies has four levels: high,
moderate, low, or very low. Data from RCTs are initially considered to be of high quality but
can be downgraded for any of five reasons: 1) risk of bias; 2) indirectness of evidence; 3) unex-
plained heterogeneity or inconsistency of results; 4) imprecision of results; or 5) high probabil-
ity of publication bias. Data from non-RCTs are considered to be of low quality, but can be
upgraded for any of three reasons: 1) large magnitude of effect; 2) plausible confounding would
increase confidence in an estimated effect; or 3) the presence of a dose-response gradient.
Results
We initially identified 492 articles (bibliographic databases, n = 408; conference abstracts,
n = 16; registered trials, n = 68). After removing 172 duplicate records and 161 clearly irrele-
vant records, we independently reviewed 159 titles and abstracts and excluded 139 clearly irrel-
evant records. We selected 20 records for full-text review. We then excluded 14 studies
reporting results of other background regimens, second-line therapy, pharmacokinetics and
other topics. Fig 1 depicts our screening process.
Two trials (reported in five published articles and one conference abstract) met our inclu-
sion criteria. (Table 1). The trials were conducted in Australia, Belgium,Canada, France, Ger-
many, Hungary, Italy, The Netherlands, Romania, Spain, Russia, the United Kingdom and the
United States. Overall, there were 934 participants. The first trial (SPRING-1) was a four-arm
Phase IIb trial that compared DTG + ABC + 3TC (N = 17) or DTG + TDF + FTC (N = 34)
with EFV + either ABC + 3TC (N = 16) or TDF + FTC (N = 34) [9, 20]. The other was a Phase
III multicenter trial (SINGLE) that compared DTG + ABC + 3TC with EFV + ABC + 3TC in
833 ART- naïve patients [11,21–23].
SPRING-1 contributed 51 patients to the DTG arm and 50 to the EFV arm; SINGLE con-
tributed 414 to the DTG arm and 419 to the EFV arm. Participants in the SPRING-1 trial who
received lower doses of DTG (53 randomized to receive 10 mg DTG and 51 randomized to
receive 25 mg of DTG daily) were not included in the analysis [20].
The primary endpoint of these two studies was viral suppression to<50 copies/mL at 48, 96
and 144 weeks. In meta-analysis at each time point, DTG-containing regimens were superior
DTG vs. EFV for Initial ART
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Fig 1. PRISMA flowchart: Flowchart depicting our screening process.
doi:10.1371/journal.pone.0162775.g001
DTG vs. EFV for Initial ART
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to EFV-containing regimens (RR = 1.10, 95% CI 1.04–1.16 at 48 weeks; RR = 1.12, 95% CI
1.04–1.21 at 96 weeks and RR = 1.13, 95% CI 1.02–1.24 at 144 weeks) (Figs 2–4). Only SINGLE
contributed data to the 144-week outcome. There were only two deaths overall (both in the
EFV arm in SINGLE) and no difference in risk of death between the two treatment regimens
(RR = 0.26, 95% CI 0.01–4.20). SINGLE also reported a primary outcome of discontinuation of
initial ART regimen because of adverse events or death at 96 and 144 weeks. At both time
points, the DTG-containing regimens were superior to those containing EFV (RR = 0.27, 955
CI 0.15–0.50 at 96 weeks and RR = 0.28, 95% CI 0.16–0.48 at 144 weeks). Risk of serious
adverse events was similar in each regimen at 96 weeks (RR = 1.15, 95% CI 0.80–1.63) and 144
weeks (RR = 0.93, 95% CI 0.68–1.29).
The principal secondary outcomes were CD4 recovery and antiretroviral resistance. SIN-
GLE and SPRING-1 contributed data to the 48 and 96-week outcomes; SINGLE alone contrib-
uted data to the 144-week outcome. At 48, 96 and 144 weeks immune recovery was
significantlymore robust among patients taking the DTG-based regimen (+57.9 cells/μL, 95%
CI +40.1 to +75.8; +42.2 cells/μL, 95% CI +16.6 to +67.9; and +46.9 cells/μL, 95% CI +15.6 to
+78.2, respectively). There was no integrase inhibitor resistance at 96 weeks in either study but
10 instances of NRTI or NNRTI resistance at 96 weeks (RR = 0.09, 95% CI 0.01–0.71). Tables 2
and 3 show results for all outcomes.
Our assessments for heterogeneity with the I2 statistic found no (0%) heterogeneity in any
meta-analysis of primary or secondary outcomes.
Subgroup analysis
SPRING-1 also compared two separate NRTI backbones with DTG and found virologic non-
response at 48 weeks in one patient in the DTG+TDF+FTC arm and one in the DTG+ABC
+3TC arm (not counting one ABC-armpatient with Burkitt’s lymphoma). Comparing data
from SPRING-1’s DTG+TDF+FTC patients (n = 34) with pooledDTG+ABC+3TCdata from
patients in both the SPRING-1 and SINGLE trials (n = 431), patients receivingDTG+TDF
+FTC in SPRING-1 had modestly better virologic response than those receiving DTG+ABC
+3TC in either trial (RR = 1.08, 95% CI 1.01–1.16).
Table 1. Characteristics of included studies.
Study Clinicaltrials.gov
identifier
Setting Participants Intervention Comparator
SINGLE NCT01263015 Canada, Denmark, France, Germany, Italy, Netherlands,
Romania, Spain, United Kingdom, United States
833 DTG+ABC+3TC EFV+ABC
+3TC
SPRING-
1
NCT00951015 France, Germany, Italy, Russia, Spain, United States 101 DTG+ABC+3TC or DTG
+TDF+FTC
EFV+ABC
+3TC
Legend: DTG, dolutegravir. ABC, abacavir. 3TC, lamivudine. FTC, emtricitabine. TDF, tenofovir.
doi:10.1371/journal.pone.0162775.t001
Fig 2. DTG + two NRTI vs. EFV + two NRTIs. Viral suppression to non-detectable (<50 copies/mL) at 48 weeks.
doi:10.1371/journal.pone.0162775.g002
DTG vs. EFV for Initial ART
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Risk of bias in the included studies
Overall, the risk of bias across both trials was moderate. In both trials, methods for sequence
generation were adequate, with centralized, computer-based procedures used to randomize
patients within baseline CD4 and viral load strata in SINGLE and within viral load strata and
NRTI selection in SPRING-1. Allocation concealment and blinding of patients and personnel
was adequate in SINGLE, although at week 96 patients and personnel were unblinded. Out-
come assessors were unblinded at week 48. In SPRING-1, however, allocation to drug was not
concealed; only drug dose was concealed. Similarly, participants and personnel were blinded
only to drug dose. Outcome assessors were blinded to both drug and dose.With all outcomes
biologicallymeasured in both trials, the risk of bias from unconcealed allocation or lack of
blinding is unclear, though it is likely low.
There was a high risk of attrition bias in SINGLE, with 18% of DTG arm participants and
26% of EFV arm participants leaving the trial by week 96. While clinical reasons for withdrawal
up to week 96 are describedwell, other types of reasons are not clearly described.Withdrawals
after week 96 were described even less clearly. In SPRING-1, attrition was low (6% in DTG
arm, 10% in EFV arm), and investigators described it adequately. With regard to selective out-
come reporting, both trials conformed well to their respective protocols, though one outcome
in SINGLE (“Change from baseline in CD4+ cells at week 48”) was reported only the clinical-
trials.gov web site and not in any published report.
Finally, it should be noted that both trials were sponsored by pharmaceutical companies.
The risk of bias this brings to the research is unclear. Although in our reviewwe detected no
obvious problems attributable to industry involvement, we describe this involvement here.
Conflict of interest forms were available for authors of the key papers. In SINGLE, the initial
2013 manuscript [11] was drafted by a named full-timeGlaxoSmithKline (GSK) company
employee. Four of 14 named authors on that paper [11] were salariedGSK employees. Another
named author was on the GSK Board. Nearly all others had received extensive personal con-
sulting fees and other financial and in-kind considerations from GSK, ViiV Healthcare and
other pharmaceutical companies. Nearly all authors on a subsequent SINGLE paper [23] were
extensively connected as employees, board members and consultants with GSK, ViiV
Fig 3. DTG + two NRTI vs. EFV + two NRTIs. Viral suppression to non-detectable (<50 copies/mL) at 96 weeks.
doi:10.1371/journal.pone.0162775.g003
Fig 4. DTG + two NRTI vs. EFV + two NRTIs. Viral suppression to non-detectable (<50 copies/mL) at 144 weeks.
doi:10.1371/journal.pone.0162775.g004
DTG vs. EFV for Initial ART
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Healthcare and other businesses. The situation in SPRING-1 was similar, with four of 11
named authors on the trial’s key paper [20] serving as salariedGSK employees.
Fig 5 provides a summary depiction of bias risk in the included studies. S2 Table provides a
detailed assessment of bias risk in each trial.
Quality of the evidence
For the key virologic suppression outcomes, evidence quality was moderate to high. There is
high quality evidence from the two trials that virologic suppression was superior at 48 weeks
with the DTG-based regimen. At 96 weeks, the two trials provide moderate quality evidence
that DTG was superior to EFV. Evidence quality was graded down one level for risk of bias due
to the high rate of attrition in SINGLE, a much larger trial than SPRING-1. The 144-week
Table 3. Continuous outcomes, DTG vs. EFV plus two NRTIs for first-line ART.
Outcomes Studies MD (95% CI) Participants
(DTG)
Participants
(EFV)
Immunologic recovery (CD4 count Δ) at 48 weeks (pooled data, SINGLE
and SPRING-1)
2 +57.93 (+40.11 to
+75.75)
465 469
Immunologic recovery (CD4 count Δ) at 96 weeks (pooled data, SINGLE
and SPRING-1)
2 +42.21 (+16.62 to
+67.81)
465 469
Immunologic recovery (CD4 count Δ) at 144 weeks (SINGLE) 1 +46.9 (+15.56 to
+78.24)
414 419
Legend: MD, mean difference; CI, confidence interval; DTG, dolutegravir-based regimen; EFV, efavirenz-based regimen.
doi:10.1371/journal.pone.0162775.t003
Table 2. Dichotomous outcomes, DTG vs. EFV plus two NRTIs for first-line ART.
Outcomes Studies RR (95% CI) Events
(DTG)
Total
(DTG)
Events
(EFV)
Total
(EFV)
Viral suppression to non-detectable (<50 copies/mL) at 48 weeks
(pooled data, SINGLE and SPRING-1)
2 1.10 (1.04 to
1.16)
417 465 383 469
Viral suppression to non-detectable (<50 copies/mL) at 96 weeks
(pooled data, SINGLE and SPRING-1)
2 1.12 (1.04 to
1.21)
376 465 338 469
Viral suppression to non-detectable (<50 copies/mL) at 144 weeks
(SINGLE)
1 1.13 (1.02 to
1.24)
294 414 264 419
Mortality at 48 weeks (pooled data, SINGLE and SPRING-1) 2 0.2 (0.01 to
4.20)
0 465 2 469
Discontinuation due to adverse events or death at 96 weeks (SINGLE) 1 0.27 (0.15 to
0.50)
13 414 48 419
Discontinuation due to adverse events or death at 144 weeks (SINGLE) 1 0.28 (0.16 to
0.48)
16 414 58 419
Clinical disease progression at 48 weeks (pooled data, SINGLE and
SPRING-1)
2 0.83 (0.45 to
1.52)
18 465 22 469
INI resistance mutation at 96 weeks (pooled data, SINGLE and SPRING-
1)
2 No events 0 465 0 469
NRTI or NNRTI resistance mutation at 96 weeks (pooled data, SINGLE
and SPRING-1)
2 0.09 (0.01 to
0.71)
0 465 10 469
Serious adverse events at 96 weeks (pooled data, SINGLE and
SPRING-1)
2 1.15 (0.8 to
1.63)
58 465 51 469
Serious adverse events at 144 weeks (SINGLE) 1 0.93 (0.68 to
1.29)
60 414 65 419
Legend: RR, risk ratio; CI, confidence interval; DTG, dolutegravir-based regimen; EFV, efavirenz-based regimen.
doi:10.1371/journal.pone.0162775.t002
DTG vs. EFV for Initial ART
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virologic suppression outcome was reported only in SINGLE and was again rated as moderate
quality evidence, graded down for risk of bias due to high attrition. There was low quality evi-
dence of no difference in mortality between regimens. Evidence quality was graded down two
Fig 5. Risk of bias. Review authors’ judgments about each risk of bias item for included studies.
doi:10.1371/journal.pone.0162775.g005
DTG vs. EFV for Initial ART
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levels for very serious imprecision (very few events). There was moderate quality evidence
from the two trials of no difference between regimens in regard to clinical disease progression
at 48 weeks. Evidence quality was graded down one level for serious imprecision (few events).
There was low quality evidence from one trial for strikingly less discontinuation due to
adverse events or death at both 96 and 144 weeks. Evidence quality was graded down one level
for serious risk of bias (high attrition) and one level for serious imprecision (few events). Evi-
dence quality was not graded up for large effect due to the serious risk of bias and serious
imprecision. There was low quality evidence of no difference between regimens in terms of
serious adverse events both at 96 weeks (two trials) and at 144 weeks (one trial). Evidence qual-
ity was graded down one level for serious risk of bias (high attrition) and one level for serious
imprecision (few events).
The two trials contributed high quality evidence of improved immunologic recovery at 48
weeks. One trial provided moderate quality evidence of continued immunologic recovery at 96
and 144 weeks. Evidence quality was graded down one level for risk of bias in these outcomes,
due to the high rate of attrition. See S3 Table for our complete GRADE evidence profile analy-
sis of evidence quality.
Discussion
We found that DTG-containing regimens were associated with a greater proportion of patients
being virologically suppressed up to 144 weeks after initiation of therapy. We also found that
participants in the DTG-containing regimens were almost four-times less likely to discontinue
their original regimen because of adverse events or to die than those in the EFV arms. Finally,
no participants in the DTG arm developed resistance to integrase inhibitors, while 10 in the
EFV arm developed either NRTI or NNRTI resistance.
We also found that patients who were randomized to receive a TDF/FTC backbone were
slightly more likely to reach a virologic suppression endpoint than those randomized to receive
ABC/3TC. In an exploratory analysis of pooled data from SINGLE and two other trials
(SPRING-2 and FLAMINGO, respectively comparing DTG with raltegravir and ritonavir-
boosted darunavir in first-line regimens), investigators found no difference betweenTDF/FTC
and ABC/3TC backbones [23]. DTG is co-formulated with ABC+3TC, and for this reason
ABC/3TC is the preferred NRTI backbone. Patients initiating ABC+3TC should be screened
for predisposition for ABC hypersensitivity reactions with HLA-B5701 testing if such testing
is available [3,4,5]. Also ABC+3TC should be avoided in patients with baseline viral loads
>100,000 copies/mL [3,5], but this recommendation has not beenmade for DTG [3]. On the
other hand, TDF should be avoided in patients with osteoporosis and impaired renal function
[3,4,5].
WHO’s decisions regarding what therapies to recommend are based on a standardized
process that includes multiple inputs [24,25]. The first input is an assessment of efficacy,
which includes both a systematic review and an assessment of the quality of the evidence
using GRADE evidence profiles. Additional inputs include values and preferences of the
intended recipients of the proposed therapy and resource use that adoption of the interven-
tion would require. From these inputs a recommendation is made by a guideline develop-
ment group to adopt or to not adopt a recommendation and to rate the recommendation as
strong or conditional. In this review, we compared DTG-containing first-line regimens with
the current standard of EFV plus two NRTIs and assessed the quality of the evidence. Values
and preferences and resource use will have to be determined separately in order to proceed
with a recommendation.
DTG vs. EFV for Initial ART
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As with any systematic review our study is limited by the sensitivity of our search and our
ability to identify studies that meet our inclusion criteria.We attempted to minimize this risk
by comprehensively searching four key databases and hand searching abstracts from three
major conferences as well as the bibliographies not only of included articles but also of review
articles. Secondly, the two trials on which our conclusions are based were conducted in Austra-
lia, Europe and North America; given that the large majority of HIV-infected patients are in
Africa and Asia, this may limit the generalizability of our findings. Finally we used the GRADE
system to rate the quality of this literature. A recent evaluation of how GRADE is being used at
WHO found some remaining challenges [25], but it has emerged as the gold standard for
guideline development at WHO [24] and is required by the Guideline ReviewCommittee,
which approves all new guidelines.
Conclusions
We found two RCTs that directly compared DTG and EFV-containing three-drug regimens
for initial treatment of HIV infection in adults and adolescents. DTG appears to be superior to
EFV in terms of durable viral suppression, absence of resistance and immunologic recovery.
DTG-containing regimens should be considered in future international guidelines for initial
therapy of HIV infection.
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